Revenue: As of FY2025, the actual value is USD 1.635 B, beating the estimate of USD 1.63 B.EPS: As of FY2025, the actual value is USD -6.74, missing the estimate of USD -6.2233.EBIT: As of FY2025, the actual value is USD -425.59 M.<h3>Segment Revenue</h3><ul><li>Codman Specialty Surgical (CSS): Net revenues for the year ended December 31, 2025, were $1,200.5 million, an increase of 5.0% from $1,143.6 million in the prior year. This increase was primarily due to the timing of the Acclarent acquisition and CSF Management shipping holds experienced in the prior year, excluding a $6.5 million impact from foreign currency fluctuations. </li><li>Tissue Technologies (TT): Net revenues for the year ended December 31, 2025, were $434.7 million, a decrease of 6.9% from $466.9 million in the prior year. This decrease was mainly attributed to quality and operational issues with MediHoney and reduced private label revenues, partially offset by growth in Integra Skin and DuraSorb. </li><li>Total Revenues: Total revenues increased by $24.7 million, or 1.5%, to $1,635.2 million in 2025 from $1,610.5 million in 2024. </li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: 英特格拉生命科学 reported a net loss of - $516.5 million, or - $6.74 per diluted share, for the year ended December 31, 2025, compared to a net loss of - $6.9 million, or - $0.09 per diluted share, for the year ended December 31, 2024. The increased net loss in 2025 was primarily due to a $511.4 million goodwill impairment charge. </li><li>Gross Margin: Gross margin was $831.6 million in 2025, a decrease of $50.4 million from $882.1 million in 2024. As a percentage of total revenues, gross margin decreased to 50.9% in 2025 from 54.8% in 2024, impacted by quality and operational issues, higher manufacturing costs, and tariffs. </li><li>Operating Expenses: Total operating expenses increased by $471.3 million, or 55.2%, to $1,325.0 million in 2025, from $853.7 million in 2024, primarily driven by the goodwill impairment. <ul><li>Research and Development: Expenses decreased by $16.4 million in 2025 compared to 2024. </li><li>Selling, General and Administrative: Expenses decreased by $17.3 million in 2025. </li><li>Goodwill Impairment: A charge of $511.4 million was recognized in 2025. </li><li>Intangible Asset Amortization: Amortization expense was $15.0 million in 2025, down from $21.3 million in 2024. </li></ul></li><li>Special Charges: Total special charges were $149.7 million in 2025, compared to $147.4 million in 2024. </li><li>Interest Expense: Increased by $15.6 million to - $86.3 million in 2025 from - $70.6 million in 2024, mainly due to higher interest rates on borrowings under the revolving credit facility. </li></ul><h3>Cash Flow</h3><ul><li>Net Cash Provided by Operating Activities: Decreased by $79.0 million to $50.4 million in 2025, compared to $129.4 million in 2024. </li><li>Net Cash Used in Investing Activities: Decreased to - $108.1 million in 2025 from - $390.8 million in 2024. Key uses in 2025 included $81.4 million for capital expenditures and $14.2 million for intangible asset purchases. </li><li>Net Cash Provided by Financing Activities: Decreased to $28.3 million in 2025 from $237.9 million in 2024. In 2025, this included - $575.0 million for repayment of 2025 Notes and $720.7 million in proceeds from long-term indebtedness borrowings. </li></ul><h3>Unique Metrics</h3><ul><li>Tariff Costs: 英特格拉生命科学 incurred $19.9 million in tariff costs in 2025, with an estimated $16.0 million related to tariffs imposed under IEEPA authority, and $6.5 million recognized in cost of goods sold. </li><li>Restructuring Costs: 英特格拉生命科学 expects to incur aggregate restructuring costs of approximately $12.6 million related to severance and other employee costs through the end of 2026, with $8.5 million of these costs incurred in 2025. </li></ul><h3>Outlook / Guidance</h3>英特格拉生命科学 anticipates PMA approval for SurgiMend and DuraSorb in 2026, following the operationalization of its Braintree facility. The company expects its worldwide effective income tax rate for 2026 to be approximately 18% and plans to seek refinancing for all outstanding debt in 2026.

Integra LifeSciences | 10-K: FY2025 Revenue Beats Estimate at USD 1.635 B